(NASDAQ: LXRX) Lexicon Pharmaceuticals's forecast annual revenue growth rate of -2.72% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Lexicon Pharmaceuticals's revenue in 2026 is $69,643,000.On average, 7 Wall Street analysts forecast LXRX's revenue for 2026 to be $16,313,556,619, with the lowest LXRX revenue forecast at $13,538,217,574, and the highest LXRX revenue forecast at $20,894,998,186. On average, 7 Wall Street analysts forecast LXRX's revenue for 2027 to be $8,877,264,854, with the lowest LXRX revenue forecast at $0, and the highest LXRX revenue forecast at $25,978,825,869.
In 2028, LXRX is forecast to generate $33,889,519,379 in revenue, with the lowest revenue forecast at $3,177,780,974 and the highest revenue forecast at $69,041,444,898.